anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Immune-mediated seizures are rare but are increasingly recognized as an etiology of seizures resistant to anti-seizure medications (ASMs). Antibody Prevalence in Epilepsy 2 (APE2) and Response to Immunotherapy in Epilepsy 2 (RITE2) scores were developed recently to identify patients who may be seropositive for serum central nervous system (CNS) specific antibodies (Ab) and may benefit from immunotherapy (Dubey et al. 2018). The goal of this study was to apply APE2 and RITE2 scores to an independent cohort of patients with seizures secondary to autoimmune encephalitis (AE) and to further verify the sensitivity and specificity of the scores.
PRINCIPAL RESULTS: We conducted a retrospective study at Stanford University Hospital between 2008 and 2021 and included patients who had acute seizures and AE using diagnostic criteria from Graus (n = 34 definite AE, 10 probable AE, and 12 possible AE) (Graus et al. 2016). Patients were excluded if they did not have a serum Ab panel investigated or had alternate diagnoses (n = 55). APE2 and RITE2 scores were calculated based on clinical and diagnostic data (n = 56). Serum Ab were positive in 73 % of patients, in which 63 % cases carried CNS specific Ab. An APE2 score ≥ 4 had a sensitivity of 97 % and specificity of 14 % to predict a positive serum CNS specific Ab. A RITE2 score ≥ 7 had a sensitivity of 93 % and specificity of 60 % to predict seizure responsiveness to immunotherapy.
CONCLUSION: APE2 and RITE2 scores had high sensitivities but low specificities to predict seropositivity and seizure responsiveness to immunotherapy in patients with autoimmune encephalitis with seizures.
The present disclosure describes systems and methods for immunotherapies Immune cells can be engineered to exhibit enhanced half-life as compared to control cell (e.g., a non-engineered immune cell). Immune cells can be engineered to exhibit enhanced proliferation as compared to a control cell. Immune cells can be engineered to effectively and specifically target diseased cells (e.g., cancer cells) that a control cell otherwise is insufficient or unable to target. The engineered Immune cells disclosed herein can be engineered ex vivo, in vitro, and in some cases, in vivo. The engineered Immune cells that are prepared ex vivo or in vitro can be administered to a subject in need thereof to treat a disease (e.g., myeloma or solid tumors). The engineered Immune cells can be autologous to the subject. Alternatively, the engineered immune cells can be allogeneic to the subject.
Endothelial dysfunction denotes abnormal contractile function of the inner lining of blood vessels. Endothelial dysfunction is associated with hypertension, hypercholesterolemia, atherosclerosis and diabetes and is an independent risk factor for cardiovascular disease. In normal physiology, endothelial cells synthesize and release factors that modulate blood vessel growth, inflammation, homeostasis, and vascular tone. Recently, endothelial dysfunction has been recognized as an early event in ischemia-reperfusion (IR) injury. IR injury causes damage to tissue and is important in many settings including acute coronary artery occlusions and cerebral ischemia. A model to examine the physiology of IR induced endothelial dysfunction and to test pharmacologic agents to prevent IR induced endothelial dysfunction is of paramount importance given the rise in cardiovascular and cerebrovascular disease. Recently in Protocol 06-H-0024, our group found that 20 minutes of ischemic stress causes no absolute endothelial dysfunction to the forearm using venous plethysmography to measure blood flow, despite numerous publications that support this model. We believe that the previously published data are based on a computational error resulting in an erroneous data interpretation (discussed in the introductory section of this proposal). Using NMR spectroscopy in protocol 06-H-0024 we have found that by adding exercise to exhaustion (usually 1 to 2 minutes of concentric exercise) to a 15-minute period of forearm ischemia results in a significantly more robust metabolic stress to the forearm, than 20 minutes of ischemia alone. Given the potential utilization of the restoration of endothelial function as a therapeutic strategy, we propose this pilot study to examine whether 15 minutes of ischemia with exercise to exhaustion (usually 1-2 minutes of concentric exercise) will cause transient IR dependent blunting of endothelial vasodilation as measured by venous plethysmography. In this study, an extension of Protocol 06-H-0024, we hypothesize that in human subjects the addition of concentric exercise to exhaustion, as a means to deplete high energy phosphate stores, will contribute to the development of transient endothelial dysfunction when performed in parallel with a 15-minute forearm ischemic stress. The establishment of a human system to enable the study of transient forearm vessel endothelial dysfunction will enable us to explore therapeutic interventions to protect against endothelial dysfunction.
Inhaled corticosteroids (ICS) are considered first-line therapy for the management and control of patients with persistent asthma. Use of inhaled steroids has been associated with improved lung function, diminished symptoms, and fewer exacerbations. However studies show considerable inter-subject variability in ICS response. It has also been estimated that corticosteroid resistance accounts for half of all asthma-related health care costs. Therefore, identifying factors associated with ICS response is both clinical and economically important. African-American patients have been understudied with respect to genetic predictors of asthma controller medication response, and to date there have been no sufficiently powered genome-wide association studies of ICS treatment response among African American individuals with asthma. This issue is of particular importance, since African-American individuals are disproportionately affected by asthma-related complications. In this proposal, we seek to identify novel genetic loci associated with ICS treatment responsiveness (defined by the change in Asthma Control Test score) among African American individuals treated with beclomethasone dipropionate (BD) for 6 weeks. We will attempt to validate loci identified in the discovery set by 1) reassessing these variants for their interaction with ICS treatment on asthma exacerbations in a separate group of African American individuals with asthma, and 2) by reexamining the genetic association with change in asthma control among similarly treated (i.e., treatment with 6 weeks of BD) European Americans with asthma.
The control group will not participate in the Bystander Intervention Program for Dating Violence, an interview consisting of one session is planned considering for the placebo effect. The control group students will be given a single 60-minute information session on dating violence and the students will be expected to fill out the scales to be filled out within the scope of the research at the pre-test and post-test times. At the end of the study, the Bystander Intervention Program for Dating Violence will be carried out with the voluntary participants in the control group, taking into account the ethics.
Subjects will be orally supplemented with calcium acetate for 12 weeks. Subjects will be instructed to take a volume of the oral liquid solution that contains 1,334 mg of calcium acetate 3x per day with meals, for a total dose of 4,000 mg/day. Calcium acetate will be compounded by the CU Anschutz Medical Campus Research Pharmacy and dispensed to subjects in 4-week supplies.
The behavioral physical activity (PA) intervention focuses on walking, or stepping in place when it is not possible to walk (e.g., stormy weather). The primary goal of the PA intervention is to achieve at least 30 minutes per day of walking/stepping in place. The secondary goal is to use a PA tracker (e.g., the Fitbit Charge 3 provided by the intervention) to log and review walking/stepping, and to accumulate at least 3,000 steps during their 30 minutes of walking/stepping each day.
FIELD: medicine, technology of medicinal agents, pharmacy. SUBSTANCE: method involves the following stages: powder-like, dried, non-defibrinated blood of Siberian stag, Manchurian wapiti or sika deer is subjected for microcapsulation by preparing the preliminary soaking 8-10% aqueous solution of the above-indicated powder at temperature 30-35 C followed by addition of accessory material to prepared solution. Then the prepared solution is applied on microgranules made of accessory material in granulator device with fluidized bed and with their simultaneous drying. Then accessory-base material envelope is applied on microgranules surface, dried at temperature 38-40 C up to humidity 2%, not less, and calcium stearate is added in granulator device before unloading. Sugar and/or lactose, and/or glucose, and/or fructose, and/or sorbitol are used as accessory material. Ascorbic acid can be used as supplement that is added to solution of accessory material used in envelope applying. Method ensures to prepare preparations showing the enhanced fitness time and no requiring special storage conditions. EFFECT: improved method of preparing. 5 cl
Hydromorphone exerts its principal pharmacological effects on the CNS and smooth muscle, including the gastrointestinal tract. These effects are expressed and modulated by binding to specific opioid receptors. Hydromorphone is principally an agonist of mu-receptors, showing a weak affinity for k-receptors. Analgesia occurs as a consequence of the binding of hydromorphone to the mu-receptors of the CNS. Although estimates vary (from 2 to 10 times), oral hydromorphone appears to be approximately 5 times as potent (by weight) as morphine. Respiratory depression occurs principally by direct action on the cerebral respiratory control centers. Hydromorphone may cause nausea and vomiting due to direct stimulation of the chemoreceptor for emesis in the posterior area of the medulla.

Central Nervous System   
Hydromorphone produces dose-related respiratory depression by direct action on brain stem respiratory centers. The respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension and to electrical stimulation.

Hydromorphone depresses the cough reflex by direct effect on the cough center in the medulla.

Hydromorphone causes miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomic. Marked mydriasis, rather than miosis, may be seen due to severe hypoxia in overdose situations.

Gastrointestinal Tract and Other Smooth Muscle   
Hydromorphone decreases gastric, biliary and pancreatic secretions, and causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm resulting in constipation. Hydromorphone also can cause an increase in bilary tract pressure as a result of spasm of the sphincter of Oddi.

Cardiovascular System   
Hydromorphone may produce peripheral vasodilation which may result in orthostatic hypotension. Release of histamine may occur with or without associated peripheral vasodilation. Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes, and sweating.

Endocrine System   
Opioid agonists have been shown to have a variety of effects on the secretion of hormones. Opioids inhibit the secretion of adrenocorticotropic hormone (ACTH), cortisol, and luteinizing hormone (LH) in humans. They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs. Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.
The invention discloses a plant feed additive for preventing and treating diarrhea of weaned piglets and a preparation method thereof. Belongs to the technical field of feed additives. The composition comprises the following components in parts by mass: 100-150 parts of codonopsis pilosula, 100-200 parts of astragalus membranaceus, 100-200 parts of rhizoma atractylodis, 100-200 parts of acanthopanax senticosus, 200-300 parts of malt, 50-200 parts of hawthorn, 100-200 parts of dried orange peel, 50-150 parts of dandelion, 50-100 parts of Chinese pulsatilla root and 100-200 parts of honeysuckle. Compared with the prior art, the invention has the following beneficial effects: can enhance the disease resistance and immunity of piglets, promote digestion and absorption of piglets, promote growth and effectively prevent diarrhea. Interaction and synergy among the raw materials. The drug effect is greatly improved by the fermentation process. After fermentation, the activity and palatability of natural plant effective substances are improved, and the natural plant effective substances are safe and have no toxic or side effect.
PURPOSE: To obtain an antiviral agent having potent antiviral, action, thus effective for various viral diseases such as herpes virus infectious diseased and AIDS, containing, as active ingredient, a cyclobutane derivative having specific structure. CONSTITUTION: This antiviral agent contains as active ingredient a (1R,2R,3S) cyclobutane derivative of formula I (B is a purine base; R<4> is H or a protecting group) e.g. 9-[(1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutan-1-yll-adenine}. The compound of formula I is obtained, for example, by reaction between a compound of formula II (X is an eliminable group) and a purine base such as adenine, guanine or 2-aminopurine. It is preferable that the above reaction be carried out at room temperature to 170 deg.C in a solvent such as DMF using 1-5 equivalents of the purine base per equivalent of the compound of formula II. The compound of formula I can be orally, intravenously or percutaneously administered, its dose being normally 0.1-500mg/kg b.w. a day.
This is a phase I/II, open label, single-arm, single-site clinical trial designed to evaluate the safety and antiviral activity of the ApB DC vaccine, a therapeutic vaccine derived from autologous dendritic cells loaded with autologous HIV-1 infected apoptotic cells. The study will be conducted in three phases. The first is the pre-vaccination phase that includes study entry, isolation of autologous virus, and initiation of antiretroviral therapy. Once the patient's viral load has been suppressed to undetectable levels (\<50 copies/mL) and sufficient virus has been isolated, the second phase will begin. This includes leukapheresis in order to harvest monocytes and lymphocytes necessary for vaccine preparation. Three vaccine doses will be administered subcutaneously every other week. Six weeks after the last vaccination, the third phase, analytic treatment interruption (ATI) phase, will begin. A fourth, booster dose of vaccine will be given two weeks after the start of treatment interruption. The treatment interruption will be continued for twelve weeks after which the primary HIV provider will decide whether or not antiretroviral therapy should be restarted. CD4 and viral load will be closely monitored throughout the study especially during treatment interruption. Follow-up will be continued for 24 weeks after the 12-week treatment interruption.
Genetic causes account for 10-15% of male factor infertility, making the genetic investigation an essential and useful tool, mainly in azoospermic and severely oligozoospermic men. In these patients, the most frequent findings are chromosomal abnormalities and Y chromosome long arm microdeletions, which cause a primary severe spermatogenic impairment with classically increased levels of FSH. On the other hand, polymorphisms in the FSH receptor (FSHR) and FSH beta chain (FSHB) genes have been associated with different FSH plasma levels, due to variations in the receptor sensitivity (FSHR) or in the production of FSH from the pituitary gland (FSHB). Here, we describe an unusual patient with a combined genetic alteration (classic AZFc deletion of the Y chromosome and TT homozygosity for the -211G>T polymorphism in the FSHB gene (rs10835638)), presenting with cryptozoospermia, severe hypospermatogenesis, and normal LH and testosterone plasma concentrations, but low FSH levels. The patient partially benefitted from treatment with FSH (150 IU three times/week for 6 months) which allowed him to cryopreserve enough motile spermatozoa to be used for intracytoplasmic sperm injection. According to our knowledge, this is the first report of an infertile man with AZFc microdeletion with low FSH plasma concentrations related to homozygosity for the -211G>T polymorphism in the FSHB gene.
The present invention relates to an enema for treating diseases, such as pelvic inflammation, etc. The enema contains the following crude drug raw material components by weight: 12 to 24% of honeysuckle flower, 12 to 24% of common cnidium fruit, 8 to 18% of dandelion, 8 to 18% of wild chrysanthemum, 8 to 18% of philippine violet herb, 8 to 18% of semen coicis, 6 to 16% of dahurian patrinia herb, 6 to 16% of caulis sargentodoxae, 5 to 10% of red peony root, 5 to 10% of yanhusuo and 4 to 9% of szechwan chinaberry fruit, and the sum of the components is 100%. The preparation method comprises the following steps: extracting the raw materials by ethanol; steaming and filtrating dregs of medicine and the raw materials, such as the dandelions, the dahurian patrinia herb, the caulis sargentodoxae several times; mixing and concentrating the steamed and filtrated substances with extracting solution. The enema can be produced by extracting, concentrating, dissolving, diluting, filtering, sterilizing and packing. When the enema is used, the enema is diluted into enema liquid and is heated to 36 to 43 DEG C. When the enema is used, a special tool is arranged in a package box in order to clyster. The enema is suitable for treating common diseases and frequently encountered diseases, such as gynecology inflammation, menorrhagia, infertility, etc., the action is rapid and the curative effect is obvious.
OBJECTIVE AND RATIONALE: To identify and appraise current national and international clinical menopause guidance documents, and to extract and compare the recommendations of the most robust examples.
DESIGN: Systematic review.
DATA SOURCES: Ovid MEDLINE, EMBASE, PsycINFO and Web of Science ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Practice guidance documents for menopause published from 2015 until 20 July 2023. Quality was assessed by the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument.
RESULTS: Twenty-six guidance papers were identified. Of these, five clinical practice guidelines (CPGs) and one non-hormonal therapy position statement met AGREE II criteria of being at least of moderate quality. The five CPGs listed symptoms associated with the perimenopause and menopause to be vasomotor symptoms (VMS), disturbed sleep, musculoskeletal pain, decreased sexual function or desire, and mood disturbance (low mood, mood changes or depressive symptoms). Acknowledged potential long-term menopause consequences were urogenital atrophy, and increased risks of cardiovascular disease and osteoporosis. VMS and menopause-associated mood disturbance were the only consistent indications for systemic menopausal hormone therapy (MHT). Some CPGs supported MHT to prevent or treat osteoporosis, but specific guidance was lacking. None recommended MHT for cognitive symptoms or prevention of other chronic disease. Perimenopause-specific recommendations were scant. A neurokinin 3B antagonist, selective serotonin/norepinephrine (noradrenaline) reuptake inhibitors and gabapentin were recommended non-hormonal medications for VMS, and cognitive behavioural therapy and hypnosis were consistently considered as being of potential benefit.
DISCUSSION: The highest quality CPGs consistently recommended MHT for VMS and menopause-associated mood disturbance, whereas clinical depression or cognitive symptoms, and cardiometabolic disease and dementia prevention were not treatment indications. Further research is needed to inform clinical recommendations for symptomatic perimenopausal women.
315,709. Pharmagans Pharmaceutisches Institut L. W. Gans Akt.-Ges. July 16, 1928, [Convention date]. Medicines for internal use.-Hormones or their compounds, or substances containing hormones, such as are normally insoluble in oils or fats, are formed into colloidal dispersions in animal or vegetable oils or fats, for instance in butter or margarine. Additional substances, preferably lipoids such as egg yolk, may also be present. The hormone may be dispersed by treatment in a colloid mill with the oil or fat or part thereof. or may be first subdivided to colloidal dimensions, either alone or with the additional substances, and then treated with the oil or fat. It is stated that the colloidally dispersed hormones react, after some time, with the oil or fat, with formation of true solutions. The preparations are stated to be stable on keeping, and to be resistant to attack by digestive fluids and thus suitable for administration by the mouth. Hormones specified are insulin, thyroxin, adrenalin, and the active substances of the supranenal cortex and of the anterior and posterior lobes of the hypophysis. The oil or fat used, or the additional substances, or both are preferably such as to cause reflux of bile in the stomach. The Specification as open to inspection under Sect. 91 (3) (a) refers generally to solutions of hormones in oils or in oil-like substances such as glycerides of oleic acids, and states that solutions may be prepared by preliminary conversion of the hormones into salts of oleic or hydrochloric acids, or by treatment with formamide, butyramide, or bile acids or their salts. The oil-soluble compounds may be prepared in presence of the oil by using as a solvent a substance such as oleic acid. Ovarial hormones, and endocrine gland preparations in general, are referred to. This subject-matter does not appear in the Specification as accepted..
The marker 1 comprises an outer biodegradable, non toxic polymer shell 1, prepared from a biodegradable polymer such as copolymer of polylactic acid and polyglycolide. Inside the shell is a non-toxic fluorescent dye composition. The polymer coat is transparent in parts such that the fluorescence emission can be detected from an intact marker. The shell may contain nanospheres of soft iron 6, to facilitate magnetic separation. The marker is intended to be mixed with a drug for administration by injection or oral routes and is intended to have a lifetime similar to that of the drug. The degree of biodegradability may be modified to influence the lifetime of the marker in the body.
One group of boys will undergo a circumcision with no flip technique of Shang Ring Circumcision and receive regular follow-up to evaluate pain, operation associated adverse events, wound healing time. The Shang Ring will detach spontaneously without intervention, and the participants are asked to have a visit soon after ring detached. The last scheduled follow-up visit is at 90 days.